| Literature DB >> 29540158 |
Masaki Okazaki1,2, Daijo Inaguma3, Takahiro Imaizumi1, Akiko Kada2, Takaaki Yaomura4, Naotake Tsuboi1, Shoichi Maruyama5.
Abstract
BACKGROUND: Patients with late referral and positive history of volume overload may have a poor prognosis after initiating dialysis due to insufficient and/or inadequate management of complications of renal failure and the lack of better dialysis preparation. Little is known about the influence of the relationship between history of volume overload and late referral on prognosis.Entities:
Keywords: Early versus late referral; Hemodialysis initiation; Predialysis nephrologist care
Mesh:
Year: 2018 PMID: 29540158 PMCID: PMC5853026 DOI: 10.1186/s12882-018-0859-8
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Flow diagram illustrating patient enrollment for the present study
Baseline characteristics of patients at dialysis initiation by referral timing to a nephrologist
| Total ( | Late referral ( | Without late referral ( | ||
|---|---|---|---|---|
| Characteristics | ||||
| Age (years), mean ± SD | 67.5 ± 13.1 | 67.0 ± 13.7 | 67.6 ± 12.9 | 0.6 |
| Male sex, | 1005 (68.1) | 183 (66.5) | 822 (68.5) | 0.5 |
| Medical history, | ||||
| Volume overload | 381 (25.8) | 97 (35.3) | 284 (23.7) | < 0.001 |
| Admission for heart failure | 308 (20.9) | 64 (23.3) | 244 (20.3) | 0.3 |
| Amputation | 24 (1.6) | 6 (2.2) | 18 (1.5) | 0.4 |
| Malignancy | 158 (10.7) | 20 (7.3) | 138 (11.5) | 0.04 |
| Comorbidity, | ||||
| Diabetes mellitus | 767 (52.0) | 129 (46.9) | 638 (53.2) | 0.06 |
| Atherosclerotic disease | 405 (27.5) | 71 (25.8) | 334 (27.8) | 0.5 |
| Coronary heart disease | 251 (17.1) | 39 (14.2) | 212 (17.7) | 0.2 |
| Valvular heart disease | 99 (6.7) | 13 (4.7) | 86 (7.2) | 0.1 |
| Aortic disease | 83 (5.6) | 20 (7.3) | 63 (5.3) | 0.2 |
| Peripheral artery disease | 76 (5.2) | 21 (7.6) | 55 (4.6) | 0.04 |
| Cerebrovascular disease | 136 (9.2) | 24 (8.7) | 112 (9.3) | 0.8 |
| Chronic obstructive pulmonary disease | 50 (3.4) | 11 (4.0) | 39 (3.3) | 0.5 |
| Peptic ulcer disease | 51 (3.5) | 14 (5.1) | 37 (3.1) | 0.1 |
| Liver disease | 67 (4.5) | 12 (4.4) | 55 (4.6) | 0.9 |
| Dementia | 148 (10.0) | 37 (13.5) | 112 (9.3) | 0.04 |
| Laboratory values | ||||
| Hemoglobin (g/dL), mean ± SD | 9.4 ± 1.5 | 8.8 ± 1.8 | 9.5 ± 1.4 | < 0.001 |
| Serum albumin (g/dL), mean ± SD | 3.2 ± 0.6 | 3.0 ± 0.6 | 3.2 ± 0.6 | < 0.001 |
| eGFR (mL/min per 1.73 m2), mean ± SD | 5.5 ± 2.2 | 5.9 ± 3.3 | 5.4 ± 1.9 | 0.01 |
| Potassium (mEq/L), mean ± SD | 4.5 ± 0.8 | 4.6 ± 1.0 | 4.5 ± 0.8 | 0.3 |
| Adjusted calcium (mg/dL), mean ± SD | 8.6 ± 1.1 | 8.6 ± 1.2 | 8.6 ± 1.0 | 0.5 |
| Phosphate (mg/dL), mean ± SD | 6.4 ± 1.9 | 6.7 ± 2.4 | 6.3 ± 1.7 | < 0.001 |
| Charlson comorbidity index | 4.8 ± 1.8 | 5.0 ± 2.0 | 4.8 ± 1.8 | 0.2 |
| Dialysis modality, | ||||
| Peritoneal dialysis | 104 (7.1) | 11 (4.0) | 93 (7.8) | 0.03 |
| Initial dialysis access, | < 0.001 | |||
| Arteriovenous fistula | 987 (67.6) | 108 (39.3) | 879 (73.3) | |
| Arteriovenous graft | 94 (6.4) | 15 (5.5) | 79 (6.6) | |
| Central venous catheter | 289 (19.8) | 139 (51.3) | 150 (12.6) | |
| Peritoneal catheter | 86 (5.9) | 8 (2.9) | 78 (6.5) | |
| Other | 19 (1.3) | 5 (1.8) | 14 (1.2) | |
| Oral medication, | ||||
| ARB | 850 (57.7) | 98 (35.6) | 752 (62.8) | < 0.001 |
| ACE inhibitors | 131 (8.9) | 16 (5.8) | 115 (9.6) | 0.05 |
| β-Blockers | 519 (35.2) | 80 (29.1) | 439 (36.6) | 0.02 |
| Calcium antagonist | 1178 (79.9) | 184 (66.9) | 994 (82.8) | < 0.001 |
| Aldosterone antagonist | 75 (5.1) | 13 (4.7) | 62 (5.2) | 0.8 |
| Statins | 596 (40.4) | 76 (27.6) | 520 (43.3) | < 0.001 |
| Loop diuretics | 979 (66.4) | 144 (52.4) | 835 (69.6) | < 0.001 |
| Vitamin D receptor activator | 405 (27.5) | 40 (14.5) | 365 (30.2) | < 0.001 |
| Antiplatelet agents | 450 (30.5) | 68 (24.7) | 382 (31.8) | 0.02 |
| Conditions at first dialysis session | ||||
| Presence of heart failure symptoms, | 452 (30.7) | 114 (41.5) | 338 (28.3) | < 0.001 |
| Predialysis body weight (kg), mean ± SD | 60.2 ± 13.8 | 58.7 ± 14.8 | 60.5 ± 13.6 | 0.05 |
| Predialysis systolic blood pressure (mmHg), mean ± SD | 151 ± 26 | 148 ± 28 | 152 ± 25 | 0.03 |
| Predialysis diastolic blood pressure (mmHg), mean ± SD | 77 ± 15 | 76 ± 18 | 77 ± 14 | 0.5 |
eGFR estimated glomerular filtration rate, ARB angiotensin-receptor blocker, ACE angiotensin-converting enzyme, SD standard deviation
Multilevel Cox proportional hazards models for late nephrologist referrals and clinical factors of all-cause mortality
| Factors of all-cause mortality (n = 1475) | Model 1a | Model 2b | Model 3c | Model 4d |
|---|---|---|---|---|
| AHR (95% CI) | AHR (95% CI) | AHR (95% CI) | AHR (95% CI) | |
| Late referral to a nephrologist |
|
|
| 1.33 (0.99–1.79) |
| Age (per year) |
|
|
|
|
| Sex (male) |
|
|
|
|
| Medical history | ||||
| Volume overload |
|
|
|
|
| Malignancy |
|
|
| |
| Comorbidity | ||||
| Diabetes mellitus | 0.98 (0.76–1.27) | 0.96 (0.75–1.24) | 0.99 (0.76–1.28) | |
| Atherosclerotic disease |
|
|
| |
| Laboratory data | ||||
| Serum albumin (g/dL) |
|
| ||
| Phosphate (mg/dL) | 1.04 (0.97–1.11) | 1.03 (0.96–1.10) | ||
| Hemoglobin (g/dL) |
| |||
AHR adjusted hazard ratio, CI confidence interval
aAdjusted for age, sex, and history of volume overload
bAdjusted for variables in model 1 plus history of malignancy and comorbidities of diabetes mellitus and atherosclerotic disease
cAdjusted for variables in model 2 plus serum albumin and phosphate
dAdjusted for variables in model 3 plus hemoglobin
Bold data is one that does not include the value 1 in the 95% confidence interval
Fig. 2The overall survival of all-cause mortality among the four groups stratified according to presence or absence of late referral and with or without history of volume overload (G, group)
Fig. 3The relationship between late referral and history of volume overload on the all-cause mortality using Cox proportional hazards models adjusted for age, sex, diabetes mellitus, atherosclerotic disease, and malignancy
All-cause mortality rates and causes of death among the four groups stratified by referral timing and history of volume overload
| G1: Not late referral without history of volume overload ( | G2: Late referral without history of volume overload ( | G3: Not late referral with history of volume overload ( | G4: Late referral with history of volume overload ( | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total number of all-cause deaths, | 133 | 29 | 66 | 32 | ||||||||||||
| Incidence rate of all-cause death, | 6.5 | 7.2 | 10.7 | 17.6 | ||||||||||||
| Cause of death | ||||||||||||||||
| Cardiovascular disease, | 45 | (34%) | 5 | (17%) | 30 | (45%) | 19 | (57%) | ||||||||
| Heart failure | 10 | (8%) | 2 | (7%) | 14 | (21%) | 9 | (27%) | ||||||||
| Coronary heart disease | 5 | (4%) | 0 | (0%) | 7 | (11%) | 5 | (15%) | ||||||||
| Sudden cardiac death | 14 | (11%) | 1 | (3%) | 4 | (6%) | 1 | (3%) | ||||||||
| Stroke | 13 | (10%) | 2 | (7%) | 3 | (5%) | 4 | (12%) | ||||||||
| Aortic disease | 3 | (2%) | 0 | (0%) | 2 | (3%) | 0 | (0%) | ||||||||
| Infection, | 33 | (25%) | 6 | (21%) | 12 | (18%) | 3 | (9%) | ||||||||
| Malignant tumor, | 32 | (24%) | 6 | (21%) | 5 | (8%) | 2 | (6%) | ||||||||
| Other, | 14 | (11%) | 10 | (34%) | 15 | (23%) | 5 | (15%) | ||||||||
| Unknown, | 9 | (7%) | 2 | (7%) | 4 | (6%) | 3 | (9%) | ||||||||
G group